1.84
-0.20 (-9.80%)
| Penutupan Terdahulu | 2.04 |
| Buka | 2.03 |
| Jumlah Dagangan | 1,050,637 |
| Purata Dagangan (3B) | 924,765 |
| Modal Pasaran | 54,473,476 |
| Harga / Pendapatan (P/E Ke hadapan) | 8.48 |
| Harga / Jualan (P/S) | 150.89 |
| Harga / Buku (P/B) | 2.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Nov 2025 |
| EPS Cair (TTM) | -1.96 |
| Nisbah Semasa (MRQ) | 0.220 |
| Aliran Tunai Operasi (OCF TTM) | -10.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.23 M |
| Pulangan Atas Aset (ROA TTM) | -191.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NRX Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.88% |
| % Dimiliki oleh Institusi | 13.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Anson Funds Management Lp | 30 Sep 2025 | 2,025,104 |
| Advisorshares Investments Llc | 30 Sep 2025 | 342,136 |
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| Chicago Partners Investment Group Llc | 31 Dec 2025 | 33,421 |
| Sjbenen Advisory, Llc | 31 Dec 2025 | 15,000 |
| Ethos Financial Group, Llc | 31 Dec 2025 | 11,900 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Ascendiant Capital, 2,508.70%) | Beli |
| Median | 37.00 (1,910.87%) | |
| Rendah | 25.00 (BTIG, 1,258.70%) | Beli |
| Purata | 36.75 (1,897.28%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 2.32 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 15 Jan 2026 | 25.00 (1,258.70%) | Beli | 2.15 |
| 03 Dec 2025 | 25.00 (1,258.70%) | Beli | 2.41 | |
| D. Boral Capital | 05 Jan 2026 | 34.00 (1,747.83%) | Beli | 2.41 |
| 03 Dec 2025 | 34.00 (1,747.83%) | Beli | 2.41 | |
| Ascendiant Capital | 02 Jan 2026 | 48.00 (2,508.70%) | Beli | 2.62 |
| HC Wainwright & Co. | 16 Dec 2025 | 40.00 (2,073.91%) | Beli | 2.10 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |